PIDI Standard Biotech (Chongqing) Ltd. (PIDI Standard )is jointly established by Guangzhou Standard Pharma, Guangdong Pidi Pharmaceutical Co., Ltd., and Vital Laboratories PVT Ltd from India.
Company profile
The company is located in Wanzhou district in Chongqing and is a world famous manufacturer of artemisinin. It is one of the key cooperated suppliers of the Clinton Foundation, the Bill & Melinda Gates Foundation/ high-content seed research and development of University of York, anti-malaria action of WHO and Global Fund. It is also one of the largest domestic manufacturers of N-Phenylglycine potassium salt.
The company owns a comprehensive phytoextraction production line, which includes equipment for extraction,chromatography ,concentration, drying and other with the annual extraction capacity of 3000t.
Under the modern management philosophy, the company practices strict management and quality supervision and control throughout the process from raw material sourcing, production, packaging to final testing of finished products. It strictly follows environmental and safety standards so as to guarantee drug quality, production safety and to reduce pollution to the environment.
International view
PIDI Standard adheres to the comprehensive implementation of the international strategy, with an international vision, to establish an internationally competitive global procurement network, marketing and service network, and with a number of world-famous multinational pharmaceutical enterprises, pharmaceutical research institutions to establish a wide range of partnerships.
Christine Lin, president of Standard Pharma and general manager of PIDI standard, has actively participated in the policy discussions on artemisinin industry held by WHO, Clinton Foundation,the Bill & Melinda Gates Foundation/ high-content seed research and development of University of York and other international organizations. And for four consecutive times she has been invited to make a presentation as the representative of China at the World Conference on Artemisinin organized by WHO .
Our Vision
PIDI Standard sticks to the tenet of safeguarding human health, takes meeting social needs as its own responsibility, and relies on advanced science and technology to continuously boost the healthy development of pharmaceutical industry in China.
△Ms. Christine Lin, the chairman of Standard Pharma, has spoken many times at international conferences on behalf of Chinese artemisinin manufacturers
